AARD_OUT_1 [2025-04-01 13:00:45 -0400] 1783 Bytes | 496 tokens | Cum: 496 tkns (6.20% of 8k)
==========================================================================

We're scouting for winners today. Its 1:00:44 PM on Tue Apr 01, 2025 -0400 and I'm looking at Aardvark Therapeutics (AARD) up to 8.7 from 7.51

Help me investigate to see if its got potential or just another dud. So, I pulled together a bunch of data for you to look over real fast.

Here's the first list of news for Aardvark Therapeutics:

C1 - Mar-31-25 04:10PM - Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights
C2 - Mar-27-25 04:18PM - Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, But Aardvark Reverses Lower
C3 - Mar-21-25 09:20AM - Soleno Therapeutics: FDA Approval May Prove To Be A Pyrrhic Victory
C4 - Mar-14-25 11:25AM - Aardvark Therapeutics, Inc. Common Stock (AARD): Among Top Insider Purchases Last Month
C5 - Mar-03-25 02:55PM - Aardvark Therapeutics (AARD): Among Stocks With At Least $10 Million In Insider Spending Recently
C6 - Feb-12-25 10:38PM - Aardvark Therapeutics Announces Pricing of Initial Public Offering

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Aardvark Therapeutics (AARD)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

AARD_OUT_3 [2025-04-01 13:00:46 -0400] 1100 Bytes | 318 tokens | Cum: 816 tkns (10.20% of 8k)
==========================================================================

Showing C1 (chunk 1 of 6): C1:
**Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights**
Date: Mar-31-25 04:10PM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/31/3052780/0/en/Aardvark-Therapeutics-Reports-Full-Year-2024-Financial-Results-and-Provides-Business-Highlights.html

March 31, 2025 16:10 ET| Source:Aardvark Therapeutics, Inc.Aardvark Therapeutics, Inc.

SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the full year ended December 31, 2024, and provided business highlights.

“Appetite represents a reward-based neurological drive and hunger represents a penalty or p

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

AARD_OUT_5 [2025-04-01 13:00:47 -0400] 1013 Bytes | 286 tokens | Cum: 1104 tkns (13.80% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-01T12:18:55Z - RBC Capital on Aardvark Therapeutics Inc (AARD): 'We See Substantial Upside Potential On Positive Da...
A2 - 2025-03-31T20:10:33Z - Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights...
A3 - 2025-03-31T20:34:29Z - Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights...
A4 - 2025-03-31T20:25:51Z - Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights | Ta...
A5 - 2025-03-28T14:34:01Z - Aardvark Therapeutics (NASDAQ:AARD) Price Target Raised to $26.00 at Bank of America...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

AARD_OUT_7 [2025-04-01 13:00:50 -0400] 924 Bytes | 274 tokens | Cum: 1380 tkns (17.25% of 8k)
==========================================================================

Showing A1 (chunk 1 of 1): A1:
**RBC Capital on Aardvark Therapeutics Inc (AARD): 'We See Substantial Upside Potential On Positive Data'**Date: 2025-04-01Source: {'uri': 'streetinsider.com', 'dataType': 'news', 'title': 'StreetInsider.com'}URL: https://www.streetinsider.com/Analyst+Comments/RBC+Capital+on+Aardvark+Therapeutics+Inc+%28AARD%29%3A+We+See+Substantial+Upside+Potential+On+Positive+Data/24579642.htmlRBC Capital analyst Brian Abrahams reiterated an Outperform rating and $21.00 price target on Aardvark Therapeutics Inc (NASDAQ: AARD).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

AARD_OUT_9 [2025-04-01 13:00:51 -0400] 407 Bytes | 106 tokens | Cum: 1535 tkns (19.19% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-02-21T18:00:00Z - Evolving Landscape of Obesity: Key Market Insights of Latest Published Different Types of Obesity | DelveInsight

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

AARD_OUT_11 [2025-04-01 13:00:54 -0400] 913 Bytes | 237 tokens | Cum: 1774 tkns (22.18% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Evolving Landscape of Obesity: Key Market Insights of Latest Published Different Types of Obesity | DelveInsight**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/02/21/3030614/0/en/Evolving-Landscape-of-Obesity-Key-Market-Insights-of-Latest-Published-Different-Types-of-Obesity-DelveInsight.htmlThe obesity market is projected to grow from 2024 to 2034 due to the rising prevalence of obesity and the extensive pipeline of emerging drugs with improved safety profiles. The article discusses different types of obesity, including hypothalamic, pediatric, POMC deficiency, and syndromic/monogenic obesity, and the current treatment landscape and pipeline for each.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

AARD_OUT_13 [2025-04-01 13:00:55 -0400] 797 Bytes | 198 tokens | Cum: 2050 tkns (25.62% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-31 10-K It em 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the CONS financial statements and related notes ...

S2 - 2025-03-31 8-K Item 2.02 Results of Oper and Fin Cond.

On March 31, 2025, Aardvark Therapeutics, Inc. issued a press release reporting its financial results for the year ended December 31, 2024 and providing a business update. The full text of the press release is furnished a...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

AARD_OUT_15 [2025-04-01 13:01:01 -0400] 1098 Bytes | 231 tokens | Cum: 2283 tkns (28.54% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
It em 7. Managements Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the consolidated financial statements and related notes thereto included elsewhere in this Annual Report. This discussion and other parts of this Annual Report contain forward-looking statements that involve risk, assumptions and uncertainties, such as statements of our plans, objectives, expectations, intentions, forecasts and projections. Our actual results and the timing of selected events could differ materially from those discussed in these forward-looking statements as a result of several factors, including those set forth under Part I, Item 1A, Risk Factors, of this Annual Report and elsewhere in this Annual Report. You should carefully read Part I, Item 1A,

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

AARD_OUT_17 [2025-04-01 13:01:11 -0400] 5050 Bytes | 1395 tokens | Cum: 3804 tkns (47.55% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+------------------------+----------------------+
| Volume: 82,415 | Perf Month: -32.05% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+------------------------+----------------------+
| Avg Volume: 192.04K | Perf Quarter: - | Short Float: 2.72% | ROE: - |
+---------------------+-----------------------+------------------------+----------------------+
| Rel Volume: 0.82 | Index: - | Short Ratio: 1.73 | ROI: - |
+---------------------+-----------------------+------------------------+----------------------+
| RSI (14): 39.71 | Market Cap: 184.98M | Short Interest: 0.33M | Sales Surprise: - |
+---------------------+-----------------------+------------------------+----------------------+
| ATR (14): 1.52 | Shs Outstand: 21.38M | Beta: - | EPS Surprise: 39.02% |
+---------------------+-----------------------+------------------------+----------------------+
| SMA20: -9.07% | Shs Float: 12.21M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+------------------------+----------------------+
| SMA50: -22.42% | Inst Own: 10.20% | Sales past 5Y: 0.00% | Earnings: Mar 31 AMC |
+---------------------+-----------------------+------------------------+----------------------+
| SMA200: -22.42% | Insider Own: 42.89% | Employees: - | |
+---------------------+-----------------------+------------------------+----------------------+
| Perf Week: -4.84% | Insider Trans: 18.99% | Debt/Eq: 0.01 | |
+---------------------+-----------------------+------------------------+----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Aardvark Therapeutics, Inc. (AARD) by Cormorant Asset Management, LP (Unknown Title) on 2025-02-14
- Common Stock: 800189 shares at $N/A (I)
- Common Stock: 187500 shares at $16 (I)
- Series C Convertible Preferred Stock: 6780810 shares at $N/A (I)

Inside Trans: Aardvark Therapeutics, Inc. (AARD) by Sun Nelson (Chief Financial Officer) on 2025-02-14
- Common Stock: 7001 shares at $N/A (D)
- Common Stock: 10000 shares at $16 (D)
- Series C Convertible Preferred Stock: 59332 shares at $0 (D)

Inside Trans: Aardvark Therapeutics, Inc. (AARD) by Lee Tien-Li (Chief Executive Officer) on 2025-02-14
- Common Stock: 41303 shares at $N/A (D)
- Common Stock: 16542 shares at $16 (D)
- Series A Convertible Preferred Stock: 350002 shares at $0 (D)

Inside Trans: Aardvark Therapeutics, Inc. (AARD) by Vickers Venture Fund VI Pte Ltd (Unknown Title) on 2025-02-14
- Common Stock: 1637411 shares at $N/A (I)
- Common Stock: 413491 shares at $N/A (I)
- Series A Convertible Preferred Stock: 13875429 shares at $0 (I)
- Series B Convertible Preferred Stock: 3503919 shares at $0 (I)

Inside Trans: Aardvark Therapeutics, Inc. (AARD) by Chi Jeffrey (Unknown Title) on 2025-02-14
- Common Stock: 133364 shares at $N/A (I)
- Series C Convertible Preferred Stock: 1130135 shares at $0 (I)

Inside Trans: Aardvark Therapeutics, Inc. (AARD) by Decheng Capital Global Life Sciences Fund IV, L.P. (Unknown Title) on 2025-02-14
- Common Stock: 2333887 shares at $N/A (I)
- Common Stock: 333412 shares at $N/A (I)
- Common Stock: 625000 shares at $16 (I)
- Common Stock: 625000 shares at $16 (I)
- Series C Convertible Preferred Stock: 19777363 shares at $0 (I)
- Series C Convertible Preferred Stock: 2825337 shares at $0 (I)

No transactions recorded.

No transactions recorded.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 9.04
Average Volume: 125703.64
30-Day High: 12.73
30-Day Low: 7.51
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

AARD_OUT_19 [2025-04-01 13:01:14 -0400] 676 Bytes | 167 tokens | Cum: 4167 tkns (52.09% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

AARD_IN_21 [2025-04-01 13:01:15 -0400] 126 Bytes | 29 tokens | Cum: 4260 tkns (53.25% of 8k)
==========================================================================

====================================
[2025-04-01 13:01:15] # Analysis Completed
Elapsed Time: 30.54 seconds